Wire · opportunities
Insilico Medicine reports 40% ORR at 130 mg for Pan-TEAD inhibitor ISM6331 designed ...
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
Insilico Medicine announced promising Phase 1 data for ISM6331, a generative AI-designed pan-TEAD inhibitor, showing a 40% objective response rate at 130 mg in heavily pretreated mesothelioma patients, with manageable safety and ongoing Phase 1 dose escalation ahead of Phase 2a studies.
This Wire brief sits within Fusion42's coverage of Biotech, AI Frontier Models and Drug Discovery, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Your oncology drug development just gained a new benchmark for AI-designed compounds. You must speed up integrating generative AI to stay competitive or risk falling behind innovators proving its clinical impact.
◆ Coverage
2 sources · 26 Oct 2026
◆ Related on Wire
◆ Topics